Eisai, Biogen's Alzheimer's disease drug Leqembi passes muster at FDA adcomm
Fierce Pharma
JUNE 9, 2023
After a daylong discussion among experts on an FDA advisory committee, Eisai and Biogen's Leqembi is heading into the final stretch of its regulatory review on strong footing.
352 
Let's personalize your content